Incyte (INCY) Stock Price, News & Analysis

Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Key Stats

• Today's Range: $67.95 to $68.82
• 50-Day Range: $56.80 to $71.22
• 52-Week Range: $53.56 to $83.95
• Volume: 363,129 shs
• Average Volume: 1.97 million shs
• Market Capitalization: $13.17 billion
• P/E Ratio: 212.81
• Dividend Yield: N/A
• Price Target: $74.53
• Consensus Rating: Hold

Incyte Stock Analysis - MarketRank™

Incyte scored higher than 86% of companies evaluated by MarketBeat, and ranked 124th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Incyte has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 5 buy ratings, 12 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Incyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 34.57%

Earnings Growth

Earnings for Incyte are expected to grow by 34.57% in the coming year, from $4.86 to $6.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incyte is 215.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incyte is 215.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.28.

Price to Earnings Growth Ratio

Incyte has a PEG Ratio of 0.58. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Incyte has a P/B Ratio of 3.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.29% of the float of Incyte has been sold short.

Short Interest Ratio / Days to Cover

Incyte has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Incyte has recently decreased by 2.85%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incyte does not currently pay a dividend.

Dividend Growth

Incyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.1 / 5
• Environmental Score: -2.83

Percentage of Shares Shorted

4.29% of the float of Incyte has been sold short.

Short Interest Ratio / Days to Cover

Incyte has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Incyte has recently decreased by 2.85%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.46

News Sentiment

Incyte has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Incyte this week, compared to 17 articles on an average week.

Search Interest

10 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Incyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.80% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INCY Stock Analysis - Frequently Asked Questions

How have INCY shares performed this year?

Incyte's stock was trading at $69.07 at the beginning of the year. Since then, INCY shares have decreased by 0.4% and is now trading at $68.7850.
View the best growth stocks for 2025 here.

How were Incyte's earnings last quarter?

Incyte Corporation (NASDAQ:INCY) issued its quarterly earnings data on Tuesday, April, 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.15. The business's revenue was up 19.5% compared to the same quarter last year.
Read the conference call transcript.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INCY
• CIK: 879169
• Web: www.incyte.com
• Phone: (302) 498-6700
• Fax: 302-425-2750
• Employees: 2,617
• Year Founded: 1991

Price Target and Rating

• Average Stock Price Target: $74.53
• High Stock Price Target: $107.00
• Low Stock Price Target: $52.00
• Potential Upside/Downside: +9.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.22
• Research Coverage: 18 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.32
• Trailing P/E Ratio: 213.66
• Forward P/E Ratio: 14.07
• P/E Growth: 0.58
• Net Income: $32.62 million
• Net Margins: 0.48%
• Pretax Margin: 7.13%
• Return on Equity: 2.77%
• Return on Assets: 1.77%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.04
• Quick Ratio: 2.00

Sales & Book Value

• Annual Sales: $4.24 billion
• Price / Sales: 3.12
• Cash Flow: $0.55 per share
• Price / Cash Flow: 123.50
• Book Value: $17.90 per share
• Price / Book: 3.82

Miscellaneous

• Outstanding Shares: 193,570,000
• Free Float: 159,115,000
• Market Cap: $13.23 billion
• Optionable: Optionable
• Beta: 0.67